The American Chemical Society in the ACS Chemical Neuroscience journal published Dr. Nathaniel Milton’s research on Alzheimer’s disease biochemistry 22 August 2013.

Research is focused on Alzheimer's disease and the catalase enzyme, which breaks down peroxide. Catalase is known to reverse the greying of hair by preventing the natural bleaching seen in aging..

Dr Milton says: “We have shown that the enzyme catalase has beneficial actions by preventing the toxicity of the amyloid proteins that play a key role in Alzheimer’s disease, Familial British dementia, Familial Danish dementia, Type 2 Diabetes mellitus plus Creutzfeldt-Jakob disease.

“As the lead author on this study I made the original discovery that the Alzheimer’s disease amyloid beta protein binds and inhibits catalase in 1999. We have now characterised the mechanism how the enzyme protects neurons and our work suggests that drugs developed to block interactions between catalase and amyloid peptides may have detrimental rather than beneficial effects.

“Our work also suggests that targeting the amyloid protein for Alzheimer's drug discovery may have some unwanted effects.”

Background information is on my personal website which contains links to publications and the research we have been carrying out for the past 15 years -http://www.deltaneuron.com/

Further information

Dr Nathaniel Milton

Course Leader for BSc Human and Medical Sciences Senior Lecturer in Human Physiology Department of Human and Health Sciences Faculty of Science and Technology University of Westminster

Email: [email protected]

Telephone: +44 (0) 207 911 5000 extn 64130

Dr. Milton’s personal website: http://www.deltaneuron.com/

ACS journal summary: http://pubs.acs.org/doi/abs/10.1021/cn400146a

Press and media enquiries

Contact us on:

+44 (0)20 3506 9464 (9am-5pm Monday to Friday)
+44 (0)7970 483 778

[email protected]